News and Trends 8 Sep 2022 OncoBone signs deals with three partners to work on bone metastases OncoBone Ventures has signed cooperation framework agreements with three partners. The company is a U.K. start up biotech looking to develop novel therapies for cancer patients with currently incurable bone metastases. The partners are: Okayama University in Japan, the University of Bradford in the U.K., and The Development Center for Biotechnology in Taiwan. The agreements […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Lonza and Touchlight collaboration will expands customer’s access to DNA Manufacturing partner, Lonza, has today (September 6) announced a collaboration with Touchlight, a biotech company that works with enzymatic DNA production enabling genetic medicine. Through this collaboration, Lonza says it will have the ability to expand it end-to-end offering for mRNA manufacturing with an additional source of DNA raw material. This material comes from Touchlight’s […] September 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Synaffix and Emergence in $360M technology platform deal to develop ADCs Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered into a licensing agreement of up to $360 million. The agreement will provide Emergence access on a target-specific basis to Synaffix’s antibody drug conjugate (ADC) technologies made up of Glycoconnect, HydraSpace and SYNtecan E linker payload. Under the terms of […] September 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […] September 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 Synairgen to collaborate on study of patients hospitalized due to respiratory viruses Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […] September 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Study of injection to treat schizophrenia to begin after $3M payment received A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […] September 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […] September 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose Ensysce Biosciences, Inc., a clinical-stage biotech company, and Quotient Sciences, a drug development and manufacturing accelerator, are partnering to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences is currently using […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Artificial intelligence-based algorithm to be used for reporting of lymph node status in colon cancer A collaboration looking at the development of an artificial intelligence (AI)-based digital pathology solution to detect cancer within lymph nodes from colorectal surgery cases has been announced today (August 30). Indica Labs, which works in quantitative digital pathology and image management solutions, has joined forces with The Industrial Centre for Artificial Intelligence Research in Digital […] August 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Grid Biosciences signs agreement with NIH for Epstein-Barr virus vaccine Grid Biosciences has signed a license agreement for the development of a vaccine against Epstein-Barr virus (EBV) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The agreement includes access to NIH’s patent rights in EBV envelope proteins that the virus uses to gain entry into […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Strategic collaboration announced in China to accelerate the development of bacterial drugs A strategic cooperation between Porton Advanced Solutions and Suzhou Royaltech Med Co., Ltd was announced today (August 29). The companies say the collaboration which was agreed earlier in the month (August 19) is set to integrate the resources and capabilities of both parties. The say it will jointly promote the establishment of microbial vectors used […] August 29, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Malaysian Genomics and Ajlan to explore MENA biopharma opportunities Malaysian Genomics Resource Centre Berhad, a genomics and biopharmaceutical company, has signed a memorandum of understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company. Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private […] August 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email